Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

This trial is testing a combination of immunotherapy drugs — pembrolizumab and bevacizumab, with or without an immune-activating drug called CDX-1140 — for women with recurrent ovarian, fallopian tube, or peritoneal cancer that has come back after prior treatment. **You may be eligible if...** - You are 18 or older - You have recurrent serous (low or high grade), endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer - Your cancer has come back after previous treatment (either platinum-sensitive or platinum-resistant) - You have had no more than 4 prior lines of treatment - Your BRCA gene mutation status is known **You may NOT be eligible if...** - You have had more than 4 prior lines of treatment - You have untreated brain metastases - You have serious autoimmune disease requiring steroids or immunosuppressants - You have uncontrolled high blood pressure or significant bleeding history (due to bevacizumab) Talk to your doctor to see if this trial is right for you.